CX-4945
Tocris Bioscience, part of Bio-Techne | Catalog # 8993
Potent and selective CK2α and CK2α' inhibitor. Also blocks CK2-dependent HIF-1α transcription, causes cell-cycle arrest, induces apoptosis in cancer cells and induces stem cell reprogramming
Key Product Details
Description
Potent and selective CK2α and CK2α' inhibitor. Also blocks CK2-dependent HIF-1α transcription, causes cell-cycle arrest, induces apoptosis in cancer cells and induces stem cell reprogramming
Alternative Names
Silmitasertib
Product Description
CX-4945 (Silmitasertib) is a potent and selective inhibitor of protein kinase CK2α and CK2α' (IC50 = 1 nM). It shows greater than 500-fold selectivity for CK2 over a panel of > 200 kinases. CX-4945 can be used, in combination with other small molecules, in fast chemical reprogramming protocols for the induction of human somatic cells and highly efficient generation of pluripotent stem cells (hCiPS) in a minimum of 16 days with robust repeatability and reliability. CX-4945 has antiproliferative effects in vitro as it attenuates PI3K/Akt signalling, causes cell-cycle arrest and selectively induces apoptosis in cancer cells. In models of angiogenesis, CX-4945 inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1α) transcription in cancer cells. In vivo, CX-4945 displays robust antitumor activity with concomitant reduction of the mechanism-based biomarker phospho-p21 (T145) (murine xenograft model). CX-4945 is orally bioavailable.Product Specifications
Molecular Weight
371.76
Formula
C19H11ClN3O2Na
Storage
Store at -20°C
Purity
≥98% (HPLC)
Chemical Name
Sodium 5-[(3-Chlorophenyl)amino]benzo[c]-2,6-naphthyridine-8-carboxylate
CAS Number
1309357-15-0
PubChem ID
49788959
InChI Key
ODDAAPQSODILSN-UHFFFAOYSA-M
SMILES
O=C(C1=CC(N=C(C2=C3C=NC=C2)NC4=CC(Cl)=CC=C4)=C3C=C1)O[Na]
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 37.18 | 100 | |
| DMSO | 37.18 | 100 |
Preparing Stock Solutions
for CX-4945
The following data is based on the product molecular weight 371.76
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.69 mL | 13.45 mL | 26.90 mL |
| 5 mM | 0.54 mL | 2.69 mL | 5.38 mL |
| 10 mM | 0.27 mL | 1.34 mL | 2.69 mL |
| 50 mM | 0.05 mL | 0.27 mL | 0.54 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Liuyang Highly efficient and rapid generation of human pluripotent stem cells by chemical reprogramming. Cell Stem Cell 2023 PMID: 36944335
- Wang A rapid chemical reprogramming system to generate human pluripotent stem cells. Nat.Chem.Biol. 2025 PMID: 39753706
- Siddiqui-Jain CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 PMID: 21159648
Product Specific Notices for CX-4945
For research use only
Loading...
Loading...